National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018

John J. Atherton, Andrew Sindone, Carmine G. De Pasquale, Andrea Driscoll, Peter S. MacDonald, Ingrid Hopper, Peter Kistler, Tom G. Briffa, James Wong, Walter P. Abhayaratna, Liza Thomas, Ralph Audehm, Phillip J. Newton, Joan O'Loughlin, Cia Connell, Maree Branagan

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

INTRODUCTION: Heart failure (HF) is a clinical syndrome that is secondary to an abnormality of cardiac structure or function. These clinical practice guidelines focus on the diagnosis and management of HF with recommendations that have been graded on the strength of evidence and the likely absolute benefit versus harm. Additional considerations are presented as practice points. Main recommendations: Blood pressure and lipid lowering decrease the risk of developing HF. Sodium-glucose cotransporter 2 inhibitors decrease the risk of HF hospitalisation in patients with type 2 diabetes and cardiovascular disease. An echocardiogram is recommended if HF is suspected or newly diagnosed. If an echocardiogram cannot be arranged in a timely fashion, measurement of plasma B-type natriuretic peptides improves diagnostic accuracy. Angiotensin-converting enzyme inhibitors, β-blockers and mineralocorticoid receptor antagonists improve outcomes in patients with HF associated with a reduced left ventricular ejection fraction. Additional treatment options in selected patients with persistent HF associated with reduced left ventricular ejection fraction include switching the angiotensin-converting enzyme inhibitor to an angiotensin receptor neprilysin inhibitor; ivabradine; implantable cardioverter defibrillators; cardiac resynchronisation therapy; and atrial fibrillation ablation. Multidisciplinary HF disease management facilitates the implementation of evidence-based HF therapies. Clinicians should also consider models of care that optimise medication titration (eg, nurse-led titration). Changes in management as a result of the guideline: These guidelines have been designed to facilitate the systematic integration of recommendations into HF care. This should include ongoing audit and feedback systems integrated into work practices in order to improve the quality of care and outcomes of patients with HF.

Original languageEnglish
Pages (from-to)363-369
Number of pages7
JournalThe Medical journal of Australia
Volume209
Issue number8
Publication statusPublished - 15 Oct 2018

Fingerprint

Heart Failure
Guidelines
ivabradine
Angiotensin-Converting Enzyme Inhibitors
Stroke Volume
Sodium-Glucose Transport Proteins
Mineralocorticoid Receptor Antagonists
Neprilysin
Cardiac Resynchronization Therapy
Angiotensin Receptors
Implantable Defibrillators
Quality of Health Care
Brain Natriuretic Peptide
Disease Management
Practice Guidelines
Atrial Fibrillation
Type 2 Diabetes Mellitus
Heart Diseases
Hospitalization
Cardiovascular Diseases

Cite this

Atherton, J. J., Sindone, A., De Pasquale, C. G., Driscoll, A., MacDonald, P. S., Hopper, I., ... Branagan, M. (2018). National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018. The Medical journal of Australia, 209(8), 363-369.
Atherton, John J. ; Sindone, Andrew ; De Pasquale, Carmine G. ; Driscoll, Andrea ; MacDonald, Peter S. ; Hopper, Ingrid ; Kistler, Peter ; Briffa, Tom G. ; Wong, James ; Abhayaratna, Walter P. ; Thomas, Liza ; Audehm, Ralph ; Newton, Phillip J. ; O'Loughlin, Joan ; Connell, Cia ; Branagan, Maree. / National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand : Australian clinical guidelines for the management of heart failure 2018. In: The Medical journal of Australia. 2018 ; Vol. 209, No. 8. pp. 363-369.
@article{0465f2f5911a4ea5aef18656e461cb74,
title = "National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018",
abstract = "INTRODUCTION: Heart failure (HF) is a clinical syndrome that is secondary to an abnormality of cardiac structure or function. These clinical practice guidelines focus on the diagnosis and management of HF with recommendations that have been graded on the strength of evidence and the likely absolute benefit versus harm. Additional considerations are presented as practice points. Main recommendations: Blood pressure and lipid lowering decrease the risk of developing HF. Sodium-glucose cotransporter 2 inhibitors decrease the risk of HF hospitalisation in patients with type 2 diabetes and cardiovascular disease. An echocardiogram is recommended if HF is suspected or newly diagnosed. If an echocardiogram cannot be arranged in a timely fashion, measurement of plasma B-type natriuretic peptides improves diagnostic accuracy. Angiotensin-converting enzyme inhibitors, β-blockers and mineralocorticoid receptor antagonists improve outcomes in patients with HF associated with a reduced left ventricular ejection fraction. Additional treatment options in selected patients with persistent HF associated with reduced left ventricular ejection fraction include switching the angiotensin-converting enzyme inhibitor to an angiotensin receptor neprilysin inhibitor; ivabradine; implantable cardioverter defibrillators; cardiac resynchronisation therapy; and atrial fibrillation ablation. Multidisciplinary HF disease management facilitates the implementation of evidence-based HF therapies. Clinicians should also consider models of care that optimise medication titration (eg, nurse-led titration). Changes in management as a result of the guideline: These guidelines have been designed to facilitate the systematic integration of recommendations into HF care. This should include ongoing audit and feedback systems integrated into work practices in order to improve the quality of care and outcomes of patients with HF.",
keywords = "Atrial fibrillation, Cardiac pacing, artificial, Cardiac surgery, Cardiomyopathies, Defibrillator, Heart failure",
author = "Atherton, {John J.} and Andrew Sindone and {De Pasquale}, {Carmine G.} and Andrea Driscoll and MacDonald, {Peter S.} and Ingrid Hopper and Peter Kistler and Briffa, {Tom G.} and James Wong and Abhayaratna, {Walter P.} and Liza Thomas and Ralph Audehm and Newton, {Phillip J.} and Joan O'Loughlin and Cia Connell and Maree Branagan",
year = "2018",
month = "10",
day = "15",
language = "English",
volume = "209",
pages = "363--369",
journal = "Medical Journal Australia",
issn = "0025-729X",
publisher = "Australasian Medical Publishing Co. Ltd",
number = "8",

}

Atherton, JJ, Sindone, A, De Pasquale, CG, Driscoll, A, MacDonald, PS, Hopper, I, Kistler, P, Briffa, TG, Wong, J, Abhayaratna, WP, Thomas, L, Audehm, R, Newton, PJ, O'Loughlin, J, Connell, C & Branagan, M 2018, 'National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Australian clinical guidelines for the management of heart failure 2018' The Medical journal of Australia, vol. 209, no. 8, pp. 363-369.

National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand : Australian clinical guidelines for the management of heart failure 2018. / Atherton, John J.; Sindone, Andrew; De Pasquale, Carmine G.; Driscoll, Andrea; MacDonald, Peter S.; Hopper, Ingrid; Kistler, Peter; Briffa, Tom G.; Wong, James; Abhayaratna, Walter P.; Thomas, Liza; Audehm, Ralph; Newton, Phillip J.; O'Loughlin, Joan; Connell, Cia; Branagan, Maree.

In: The Medical journal of Australia, Vol. 209, No. 8, 15.10.2018, p. 363-369.

Research output: Contribution to journalArticle

TY - JOUR

T1 - National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand

T2 - Australian clinical guidelines for the management of heart failure 2018

AU - Atherton, John J.

AU - Sindone, Andrew

AU - De Pasquale, Carmine G.

AU - Driscoll, Andrea

AU - MacDonald, Peter S.

AU - Hopper, Ingrid

AU - Kistler, Peter

AU - Briffa, Tom G.

AU - Wong, James

AU - Abhayaratna, Walter P.

AU - Thomas, Liza

AU - Audehm, Ralph

AU - Newton, Phillip J.

AU - O'Loughlin, Joan

AU - Connell, Cia

AU - Branagan, Maree

PY - 2018/10/15

Y1 - 2018/10/15

N2 - INTRODUCTION: Heart failure (HF) is a clinical syndrome that is secondary to an abnormality of cardiac structure or function. These clinical practice guidelines focus on the diagnosis and management of HF with recommendations that have been graded on the strength of evidence and the likely absolute benefit versus harm. Additional considerations are presented as practice points. Main recommendations: Blood pressure and lipid lowering decrease the risk of developing HF. Sodium-glucose cotransporter 2 inhibitors decrease the risk of HF hospitalisation in patients with type 2 diabetes and cardiovascular disease. An echocardiogram is recommended if HF is suspected or newly diagnosed. If an echocardiogram cannot be arranged in a timely fashion, measurement of plasma B-type natriuretic peptides improves diagnostic accuracy. Angiotensin-converting enzyme inhibitors, β-blockers and mineralocorticoid receptor antagonists improve outcomes in patients with HF associated with a reduced left ventricular ejection fraction. Additional treatment options in selected patients with persistent HF associated with reduced left ventricular ejection fraction include switching the angiotensin-converting enzyme inhibitor to an angiotensin receptor neprilysin inhibitor; ivabradine; implantable cardioverter defibrillators; cardiac resynchronisation therapy; and atrial fibrillation ablation. Multidisciplinary HF disease management facilitates the implementation of evidence-based HF therapies. Clinicians should also consider models of care that optimise medication titration (eg, nurse-led titration). Changes in management as a result of the guideline: These guidelines have been designed to facilitate the systematic integration of recommendations into HF care. This should include ongoing audit and feedback systems integrated into work practices in order to improve the quality of care and outcomes of patients with HF.

AB - INTRODUCTION: Heart failure (HF) is a clinical syndrome that is secondary to an abnormality of cardiac structure or function. These clinical practice guidelines focus on the diagnosis and management of HF with recommendations that have been graded on the strength of evidence and the likely absolute benefit versus harm. Additional considerations are presented as practice points. Main recommendations: Blood pressure and lipid lowering decrease the risk of developing HF. Sodium-glucose cotransporter 2 inhibitors decrease the risk of HF hospitalisation in patients with type 2 diabetes and cardiovascular disease. An echocardiogram is recommended if HF is suspected or newly diagnosed. If an echocardiogram cannot be arranged in a timely fashion, measurement of plasma B-type natriuretic peptides improves diagnostic accuracy. Angiotensin-converting enzyme inhibitors, β-blockers and mineralocorticoid receptor antagonists improve outcomes in patients with HF associated with a reduced left ventricular ejection fraction. Additional treatment options in selected patients with persistent HF associated with reduced left ventricular ejection fraction include switching the angiotensin-converting enzyme inhibitor to an angiotensin receptor neprilysin inhibitor; ivabradine; implantable cardioverter defibrillators; cardiac resynchronisation therapy; and atrial fibrillation ablation. Multidisciplinary HF disease management facilitates the implementation of evidence-based HF therapies. Clinicians should also consider models of care that optimise medication titration (eg, nurse-led titration). Changes in management as a result of the guideline: These guidelines have been designed to facilitate the systematic integration of recommendations into HF care. This should include ongoing audit and feedback systems integrated into work practices in order to improve the quality of care and outcomes of patients with HF.

KW - Atrial fibrillation

KW - Cardiac pacing, artificial

KW - Cardiac surgery

KW - Cardiomyopathies

KW - Defibrillator

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=85054752391&partnerID=8YFLogxK

M3 - Article

VL - 209

SP - 363

EP - 369

JO - Medical Journal Australia

JF - Medical Journal Australia

SN - 0025-729X

IS - 8

ER -